OSA's Digital Library

Applied Optics

Applied Optics


  • Vol. 37, Iss. 31 — Nov. 1, 1998
  • pp: 7184–7192

Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells

Michael R. Hamblin, Michael P. Bamberg, Jaimie L. Miller, and Tayyaba Hasan  »View Author Affiliations

Applied Optics, Vol. 37, Issue 31, pp. 7184-7192 (1998)

View Full Text Article

Enhanced HTML    Acrobat PDF (154 KB)

Browse Journals / Lookup Meetings

Browse by Journal and Year


Lookup Conference Papers

Close Browse Journals / Lookup Meetings

Article Tools



The photosensitizer hematoporphyrin (HP) was site specifically attached to a murine monoclonal antibody (MAb) fragment OC125F(ab′)2 directed against ovarian cancer cells and to nonspecific rabbit immunoglobulin G. The photoimmunoconjugates were positively charged and were purified by column chromatography. The OC125F(ab′)2 conjugate retained immunoreactivity with human ovarian cancer cells, and the binding was competed with unmodified MAb. Phototoxicity paralleled the cellular uptake with the OC125F(ab′)2 conjugate and the light showing selective killing of target cells compared with nontarget cells. Nontargeted conjugates and free HP produced lower levels of phototoxicity and showed no selectivity.

© 1998 Optical Society of America

OCIS Codes
(170.5180) Medical optics and biotechnology : Photodynamic therapy

Original Manuscript: April 27, 1998
Revised Manuscript: July 13, 1998
Published: November 1, 1998

Michael R. Hamblin, Michael P. Bamberg, Jaimie L. Miller, and Tayyaba Hasan, "Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells," Appl. Opt. 37, 7184-7192 (1998)

Sort:  Author  |  Year  |  Journal  |  Reset  


  1. T. Hasan, J. A. Parrish, “Photodynamic therapy of cancer,” in Cancer Medicine, 4th ed. Vol. 1, J. F. Holland, E. Frei, R. C. Bast, D. W. Kufe, D. L. Morton, R. R. Weichselbaum, eds. (Williams and Wilkins, Baltimore, Md, 1996), pp. 739–751.
  2. A. M. Fisher, A. L. Murphree, C. J. Gomer, “Clinical and preclinical photodynamic therapy,” Lasers Surg. Med. 17, 2–31 (1995). [CrossRef] [PubMed]
  3. B. W. Henderson, T. J. Dougherty, “How does photodynamic therapy work?” Photochem. Photobiol. 55, 145–157 (1992). [CrossRef] [PubMed]
  4. M. R. Hamblin, E. L. Newman, “Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins,” J. Photochem. Photobiol. B. 26, 147–157 (1994). [CrossRef] [PubMed]
  5. T. Hasan, “Photosensitizer delivery mediated by macromolecular carrier systems,” in Photodynamic Therapy: Basic Principles and Clinical Applications, B. Henderson, T. Dougherty, eds. (Marcel Dekker, New York, 1992), pp. 187–200.
  6. A. M. Richter, E. Waterfield, A. K. Jain, A. J. Canaan, B. A. Allison, J. G. Levy, “Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model,” Photochem. Photobiol. 57, 1000–1006 (1993). [CrossRef] [PubMed]
  7. R. Bachor, C. R. Shea, R. Gillies, T. Hasan, “Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres,” Proc. Natl. Acad. Sci. USA 88, 1580–1584 (1991). [CrossRef] [PubMed]
  8. N. S. Soukos, M. R. Hamblin, T. Hasan, “The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates,” Photochem. Photobiol. 65, 723–729 (1997). [CrossRef] [PubMed]
  9. M. L. Yarmush, W. P. Thorpe, L. Strong, S. L. Rakestraw, M. Toner, R. G. Tompkins, “Antibody targeted photolysis,” Crit. Rev. Ther. Drug Carrier Syst. 10, 197–252 (1993). [PubMed]
  10. T. V. Akhlynina, D. A. Jans, A. A. Rosenkranz, N. V. Statsyuk, I. Y. Balashova, G. Toth, I. Pavo, A. B. Rubin, A. S. Sobolev, “Nuclear targeting of chlorin e6 enhances its photosensitizing activity,” J. Biol. Chem. 272, 20328–20331 (1997). [CrossRef] [PubMed]
  11. D. A. Johnson, S. L. Briggs, M. C. Gutowski, R. Barton, “Anti-tumor activity of CC49-doxorubicin immunoconjugates,” Anticancer Res. 15, 1387–1393 (1995). [PubMed]
  12. D. J. Buchsbaum, V. K. Langmuir, B. W. Wessels, “Experimental radioimmunotherapy,” Med. Phys. 20, 551–567 (1993). [CrossRef] [PubMed]
  13. L. L. Houston, “Targeted delivery of toxins and enzymes by antibodies and growth factors,” Curr. Opin. Biotechnol. 4, 739–744 (1993). [CrossRef] [PubMed]
  14. P. W. Cobb, C. F. LeMaistre, “Therapeutic use of immunotoxins,” Semin. Hematol. 29, 6–13 (1992). [PubMed]
  15. R. K. Jain, “Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors,” Cancer Res. 50, 814s–819s (1990). [PubMed]
  16. T. F. DeLaney, W. F. Sindelar, Z. Tochner, P. D. Smith, W. S. Friauf, G. Thomas, L. Dachowski, J. W. Cole, S. M. Steinberg, E. Glatstein, “Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors,” Int. J. Radiat. Oncol. Biol. Phys. 25, 445–457 (1993). [CrossRef] [PubMed]
  17. K. L. Molpus, D. Kato, M. R. Hamblin, L. Lilge, M. Bamberg, T. Hasan, “Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model,” Cancer Res. 56, 1075–1082 (1996). [PubMed]
  18. R. B. Veenhuizen, M. C. Ruevekamp-Helmers, T. J. Helmerhorst, P. Kenemans, W. J. Mooi, J. P. Marijnissen, F. A. Stewart, “Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC,” Int. J. Cancer 59, 830–836 (1994). [CrossRef] [PubMed]
  19. B. A. Goff, M. Bamberg, T. Hasan, “Photoimmunotherapy of human ovarian carcinoma cells ex vivo,” Cancer Res. 51, 4762–4767 (1991). [PubMed]
  20. B. A. Goff, U. Hermanto, J. Rumbaugh, J. Blake, M. Bamberg, T. Hasan, “Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model,” Br. J. Cancer 70, 474–480 (1994). [CrossRef] [PubMed]
  21. B. A. Goff, J. Blake, M. P. Bamberg, T. Hasan, “Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model,” Br. J. Cancer 74, 1194–1198 (1996). [CrossRef] [PubMed]
  22. M. R. Hamblin, J. L. Miller, T. Hasan, “The effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells,” Cancer Res. 56, 5205–5210 (1996). [PubMed]
  23. L. R. Duska, M. R. Hamblin, M. P. Bamberg, T. Hasan, “Biodistribution of charged F(ab′)2 photoimmunoconjugates in a xenograft model of ovarian cancer,” Br. J. Cancer 75, 837–844 (1997). [CrossRef]
  24. J. A. Buczek-Thomas, N. Chen, T. Hasan, “Integrin-mediated adhesion and signalling in ovarian cancer cells,” Cell. Signal. 10, 55–63 (1998). [CrossRef] [PubMed]
  25. K. L. Molpus, D. Koelliker, L. Atkins, D. Kato, J. Buczek-Thomas, A. F. J. Fuller, T. Hasan, “Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice,” Int. J. Cancer 67, 588–595 (1996). [CrossRef]
  26. E. Larson, B. Howlett, A. Jagendorf, “Artificial reductant enhancement of the Lowry method for protein determination,” Anal. Biochem. 155, 243–248 (1986). [CrossRef] [PubMed]
  27. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” J. Immunol. Methods. 65, 55–63 (1983). [CrossRef] [PubMed]
  28. R. B. Veenhuizen, M. C. Ruevekamp, H. Oppelaar, B. Ransdorp, M. van de Vijver, T. J. Helmerhorst, P. Kenemans, F. A. Stewart, “Intraperitoneal photodynamic therapy: comparison of red and green light distribution and toxicity,” Photochem. Photobiol. 66, 389–395 (1997). [CrossRef] [PubMed]
  29. H. J. Haisma, K. R. Moseley, A. Battaile, T. C. Griffiths, R. C. Knapp, “Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors,” Am. J. Obstet. Gynecol. 159, 843–848 (1988). [PubMed]
  30. R. M. Reilly, J. Sandhu, T. M. Alvarez-Diez, S. Gallinger, J. Kirsh, H. Stern, “Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions,” Clin. Pharmacokinet. 28, 126–142 (1995). [CrossRef] [PubMed]
  31. G. B. Sivolapenko, V. Douli, D. Pectasides, D. Skarlos, G. Sirmalis, R. Hussain, J. Cook, N. S. Courtenay-Luck, E. Merkouri, K. Konstantinides, A. A. Epenetos, “Breast cancer imaging with radiolabelled peptide from complementarily-determining region of antitumour antibody,” Lancet 346, 1662–1666 (1995). [CrossRef]
  32. R. K. Jain, “Transport of molecules across tumor vasculature,” Cancer Metastasis Rev. 6, 559–593 (1987). [CrossRef] [PubMed]
  33. M. A. Clauss, R. K. Jain, “Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues,” Cancer Res. 50, 3487–3492 (1990). [PubMed]
  34. H. M. Davis, V. R. Zurawski, R. C. Bast, T. L. Klug, “Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas,” Cancer Res. 46, 6143–6148 (1986). [PubMed]
  35. T. M. Behr, W. S. Becker, M. W. Klein, H. J. Bair, J. R. Scheele, F. G. Wolf, “Diagnostic accuracy and tumor-targeting kinetics of complete versus fragmented 99mTc-labeled anti-carcinoembryonic antigen antibodies: an intraindividual comparison,” Cancer Res. 55, 5786s–5793s (1995). [PubMed]
  36. R. T. Maguire, V. L. Pascucci, A. N. Maroli, J. V. Gulfo, “Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates,” Cancer 72, 3453–3462 (1993). [CrossRef] [PubMed]
  37. S. P. Creekmore, D. S. Zaharko, “Modification of chemotherapeutic effects on L1210 cells using hematoporphyrin and light,” Cancer Res. 43, 5252–5257 (1983). [PubMed]

Cited By

Alert me when this paper is cited

OSA is able to provide readers links to articles that cite this paper by participating in CrossRef's Cited-By Linking service. CrossRef includes content from more than 3000 publishers and societies. In addition to listing OSA journal articles that cite this paper, citing articles from other participating publishers will also be listed.


Fig. 1 Fig. 2 Fig. 3
Fig. 4 Fig. 5

« Previous Article  |  Next Article »

OSA is a member of CrossRef.

CrossCheck Deposited